Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
Months after losing its hepatitis C collaboration with Janssen, Achillion is trying to cut costs.
Months after raising a $107 million series C, Arcus Biosciences has filed for a $100 million IPO.
AMPLEXOR Life Sciences: Helping Life Sciences Firms Optimize Routine Document Production
Astellas has bought out a U.S. biotech that wants to ensure cell therapy products aren’t rejected by a patient’s immune system.
Three years after its last misfire, Israeli biotech PolyPid is having another go at a Nasdaq listing, seeking $86 million to develop anti-infectives.
The increasing demand for innovation in research and the related pressures to deliver on the most promising findings from discovery are also driving the need…
Sarepta expects to resume dosing in a U.K. trial of its DMD drug golodirsen pending MHRA approval.
Nektar Therapeutics could join the growing list of biotechs opting for a takeover, according to a report that it is exploring strategic options.
ReViral has hit its primary and secondary endpoints in a small midstage trial testing its experimental med against RSV.
Buried within Swiss major Roche's fourth-quarter financials was the announcement that it was dumping a host of early- and late-stage candidates.
Solid Bio has pressed on after its plans for an IPO fell apart—with a cut-price offering for an upsized stake.
Eureka Therapeutics will advance its T-cell treatment for relapsed and refractory CD19+ non-Hodgkin lymphoma into the clinic.